Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd